Abstract
It is important to understand the real-world health care resource utilization (HCRU) and costs accompanying Chimeric Antigen Receptor T-cell (CAR-T) therapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), given its association with promising clinical outcomes. We assessed the 30-day HCRU and costs upon receiving CAR-T therapy in DLBCL patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
